[
  {
    categoryName: 'Medicines',
    groups: [
      {
        group: 'CAR-T',
        items: [
          {
            item: 'Kymriah',
            description: 'First CAR-T approved in U.S.',
            details: {
              Maker: 'Novartis',
              Notes: 'Approved in 2017. Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
          {
            item: 'Yescarta',
            description: 'Second CAR-T approved in U.S.',
            details: {
              Maker: 'Gilead Sciences',
              Notes: 'Approved in 2017. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
        ]
      },
			{
        group: 'RSV vaccines',
        items: [
          {
            item: 'Kymriah',
            description: 'First CAR-T approved in U.S.',
            details: {
              Maker: 'Novartis',
              Notes: 'Approved in 2017. Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
          {
            item: 'Yescarta',
            description: 'Second CAR-T approved in U.S.',
            details: {
              Maker: 'Gilead Sciences',
              Notes: 'Approved in 2017. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
        ]
      },
      // additional groups could go here
    ]
  },
	{
    categoryName: 'Companies',
    groups: [
      {
        group: 'Pfizer',
        items: [
          {
            item: 'Covid vaccine',
            description: 'First CAR-T approved in U.S.',
            details: {
              Maker: 'Novartis',
              Notes: 'Approved in 2017. Initially approved for pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL). Later it also got approved for adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
          {
            item: 'RSV vaccine',
            description: 'Second CAR-T approved in U.S.',
            details: {
              Maker: 'Gilead Sciences',
              Notes: 'Approved in 2017. It is approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.'
            }
          },
        ]
      },
      // additional groups could go here
    ]
  },
  // additional categories could go here
];
